No substitutes available
Alzumab L 100mg Injection contains Itolizumab, a precision-based monoclonal antibody developed to regulate the overactive immune responses seen in autoimmune disorders. It is primarily used for treating moderate to severe chronic plaque psoriasis and has also demonstrated meaningful benefits in managing rheumatoid arthritis. The medication works by targeting CD6, a specific protein found on T-cells, which play a major role in triggering inflammation. By modulating this immune pathway, Alzumab L helps reduce skin lesions, joint swelling, and flare-ups, offering patients long-term symptom relief and improved quality of life.
This treatment is administered only under medical supervision in a hospital or clinical setting to ensure safety and proper monitoring. Most patients tolerate Alzumab L well, with only mild to moderate side effects reported, especially during the initial infusions. Thanks to its targeted mechanism and favorable safety profile, Alzumab L 100mg Injection is considered a valuable option for individuals who have not responded adequately to conventional therapies. Its ability to control disease progression and restore immune balance makes it an important therapeutic choice in chronic autoimmune conditions.
Alzumab L 100mg Injection is prescribed for the management of:
Alzumab L works by targeting CD6, a key protein on T-cells involved in autoimmune activity, helping to reduce excessive immune activation and inflammation. By binding to CD6, it lowers T-cell activity, decreases skin lesions in psoriasis, and relieves joint pain, stiffness, and swelling in rheumatoid arthritis. This targeted immune modulation restores balance in an overactive immune system and helps prevent further tissue damage caused by chronic inflammation.
Side Effects of Alzumab L 100mg Injection
Like all medications, Alzumab L 100mg Injection may cause side effects. However, not everyone will experience them.
Serious Side Effects (Seek immediate medical attention):
Common Side Effects (Usually mild and temporary):
Nausea, vomiting, diarrhea
Headache
Dizziness
Abdominal discomfort
Fatigue
Mild rash or itching
Infusion-related reactions (fever, chills, flushing)
Alzumab L 100mg Injection is given as an intravenous infusion by trained healthcare professionals, and the dose or frequency is determined by your doctor based on the severity of your condition, your response to treatment, and any existing medical issues. This medication should never be self-administered.
Use with caution. Discuss potential risks and benefits with your healthcare provider before starting treatment.
Avoid alcohol, as it can increase liver strain and may worsen side effects.
Use carefully if you have lung-related issues, as these conditions may affect how the medicine is processed.
>Alzumab L 100mg Injection may cause dizziness, fatigue, or light-headedness. If you experience these symptoms, avoid driving or operating machinery for your safety.
Use only after consulting your doctor, as the safety of Alzumab L during pregnancy is not well established.
Alzumab L targets the CD6 receptor on T-cells, reducing their activation and preventing the release of inflammatory signals. This helps control autoimmune responses at the cellular level, leading to reduced inflammation and symptom relief.
Combination therapy is generally approached with caution. Alzumab L may increase the risk of infections when used with other immunosuppressants or biologics. Your doctor will evaluate the benefits and risks before recommending any combination.
Most patients experience gradual improvement in inflammation, skin lesions, or joint symptoms within a few weeks, while others may require several treatment cycles. The response time varies depending on the severity of the condition and individual immune activity.
Yes, since it suppresses T-cell activity, long-term use may slightly raise the risk of infections. Regular monitoring, early symptom reporting, and avoiding exposure to contagious illnesses are essential during treatment.
Doctors typically assess liver function, infection history, vaccination status, and overall immune health before initiating treatment. Screening for active infections is crucial, as therapy may need to be postponed until the infection is managed.
| Active ingredient | Itolizumab |
| Pharmacologic class | Immunosuppressive monoclonal antibody |
| Medication category | Immunomodulatory agent |
| Dosage forms | Injection |
The information on the Phoenix Pharmex website is shared for educational purposes only and is not a substitute for professional medical advice or treatment. Always consult a doctor for any health-related questions. Please avoid self diagnosis or delaying medical care based on this content. Our mission is to support informed decisions not replace professional medical guidance.
Life-Saving Medicines Expert
Affordable Patient-Centered Care
Authentic, Top-Quality Medicines
Careful & Timely Medicine Deliveries